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Abstract
Background: Multi-drug efflux pumps have been increasingly recognized as a major component of resistance in
P. aeruginosa. We have investigated the expression level of efflux systems among clinical isolates of P. aeruginosa,
regardless of their antimicrobial susceptibility profile.
Results: Aztreonam exhibited the highest in vitro activity against the P. aeruginosa isolates studied (64.4%
susceptibility), whereas susceptibility rates of imipenem and meropenem were both 47.5%. The MexXY-OprM and
MexAB-OprM efflux systems were overexpressed in 50.8% and 27.1% of isolates studied, respectively.
Overexpression of the MexEF-OprN and MexCD-OprJ systems was not observed. AmpC b-lactamase was
overexpressed in 11.9% of P. aeruginosa isolates. In addition, decreased oprD expression was also observed in 69.5%
of the whole collection, and in 87.1% of the imipenem non-susceptible P. aeruginosa clinical isolates. The MBL-
encoding genes blaSPM-1 and blaIMP-1 were detected in 23.7% and 1.7% P. aeruginosa isolates, respectively. The
blaGES-1 was detected in 5.1% of the isolates, while blaGES-5 and blaCTX-M-2 were observed in 1.7% of the isolates
evaluated. In the present study, we have observed that efflux systems represent an adjuvant mechanism for
antimicrobial resistance.
Conclusions: Efflux systems in association of distinct mechanisms such as the porin down-regulation, AmpC
overproduction and secondary b-lactamases play also an important role in the multi-drug resistance phenotype
among P. aeruginosa clinical isolates.
Background
Pseudomonas aeruginosa is an aerobic gram-negative
pathogen and a common etiologic agent of nosocomial
infections, especially pneumonia, in seriously ill patients
[1,2]. This species is intrinsically resistant to many anti-
microbial agents and usually develop resistance to other
antimicrobial agents during antimicrobial chemotherapy,
further limiting the available therapeutic options [3].
Bacterial efflux systems capable of ejecting antimicro-
bials are mostly encoded by chromosomal genes and
generally fall into five classes, the major facilitator
superfamily (MFS), the ATP-binding cassette (ABC)
family, the small multi-drug resistance (SMR) family, the
multi-drug and toxic compound extrusion (MATE)
family and the resistance-nodulation-division (RND)
family [4]. The RND chromosomal systems are encoded
by operons and are typically formed by three proteins,
which are located in the inner membrane, periplasm
and outer membrane of the bacterial cell [5].
Sequencing of P. aeruginosa genome revealed the pre-
sence of several RND efflux systems. Of those, MexAB-
OprM, MexCD-OprJ, MexEF-OprN and MexXY-OprM
are able to pump out multiple antipseudomonal com-
pounds [1,4,6]. Studies with MexAB-OprM mutants
demonstrated that this efflux system extrudes quino-
lones, aminoglycosides, macrolides, tetracycline, chlor-
amphenicol, novobiocin, and most b-lactams but not
imipenem [5]. The MexXY-OprM is able to eject
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any medium, provided the original work is properly cited.cefepime, cefotaxime, levofloxacin, ciprofloxacin, amika-
cin, gentamicin, tobramycin, erythromycin, tetracycline
and meropenem [5]. MexAB-OprM and MexXY-OprM
are constitutively expressed and contribute to the intrin-
s i cr e s i s t a n c ep h e n o t y p eo fP. aeruginosa. However,
when overexpressed, these efflux systems confer reduced
susceptibility to different classes of antimicrobial agents
[7,8]. Although the efflux systems MexCD-OprJ and
MexEF-OprN are quiescent in wild type P. aeruginosa,
their overexpression may also contribute to the acquired
multi-drug resistance phenotype in mutant isolates [5].
Overexpression of efflux systems generally confers
modest levels of antimicrobial resistance [9,10]. How-
ever, its association with other resistance determinants
is frequently observed [11]. In Brazil, production of
extended-spectrum b-lactamases (ESBL), such as
CTX-M (cefotaximase) and GES (Guiana-extended spec-
trum), or metallo-b-lactamases (MBL) such as SPM (São
Paulo Metallo-b-lactamase) and IMP (imipenemase) are
the main mechanisms of acquired resistance to broad-
spectrum b-lactams among P. aeruginosa clinical isolates
[12]. The association of these b-lactamases with overex-
pression of efflux pumps and/or porin loss may lead to
high level and/or co-resistance phenotypes [11]. For this
reason, efflux pumps may seriously impact antimicrobial
therapy in clinical settings. The aim of this study was to
investigate the expression of efflux systems as well as its
association with other resistance mechanisms, such as
b-lactamase production and porin down-regulation,
among P. aeruginosa clinical isolates.
Results
Bacterial isolates and antimicrobial susceptibility profile
Fifty-nine non-repetitive P. aeruginosa isolates were col-
lected from bloodstream infections between June and
December 2005. The majority of isolates was collected
from patients hospitalized in intensive care units
(64.4%), followed by the emergency room ward (28.8%)
and pediatric oncology unit (6.8%). Aztreonam showed
the highest susceptibility rate against the isolates studied
(64.4%), followed by cefepime (49.2%), meropenem
(47.2%), imipenem (47.2%), ceftazidime (44.1%), amika-
cin (40.7%), ciprofloxacin (35.6%) and gentamicin
(32.2%, Table 1). Approximately 17% of the isolates
(n = 10) were susceptible to all tested antimicrobial.
Pulsed Field Gel Electrophoresis
A total of 23 distinct PFGE patterns were detected
among the 59 P. aeruginosa clinical isolates studied.
Five P. aeruginosa isolates could not be typed by PFGE
using SpeI. Although 38 isolates were clustered in six
PFGE patterns, 16 isolates showed distinct PFGE
patterns.
Carbapenems hydrolysis and b-lactamases production
Carbapenem hydrolysis was detected in 15 P. aerugi-
nosa, representing 25.4% of the whole collection
and 48.4% of the imipenem-resistant isolates. These
isolates had their carbapenemase activity inhibited by
EDTA, and the presence of the MBL-encoding genes
blaSPM-1 and blaIMP-like was confirmed by multiplex
PCR, in 14 and 1 isolates, respectively. Among the
SPM-producing P. aeruginosa studied, 13 showed the
same PFGE pattern, whereas one isolate could not be
typed using Spe I. ESBL-encoding genes were present
in five isolates: blaGES-1 (n =3 ) ,blaGES-5 (n =1 )a n d
blaCTX-M-2 (n = 1). GES-type producers belonged to
the same genotype, whereas CTX-M-2-producer
s h o w e dau n i q u eP F G Ep r o f i l e .
Gene expression
The percentage of P. aeruginosa isolates that were non-
susceptible to antimicrobials and demonstrated overex-
pression of efflux genes and ampC, coupled with oprD
down-regulation is shown in Table 1. In addition, Table
2 shows the association of different resistance mechan-
isms identified, and antimicrobials MICs that were more
frequently observed at each association (modal MIC).
The gene expression analysis showed that 50.8%
(n = 30) and 27.1% (n = 16) of P. aeruginosa clinical iso-
lates demonstrated increased mexY (from 2.2- to 41.0-
fold) and mexB (from 2.1- to 10.0-fold) transcription
mRNA levels, respectively, compared to those of PAO1.
In addition, 11 P. aeruginosa isolates (18.6%) showed
overexpression of both mexB and mexY efflux genes.
Overexpression of MexCD-OprJ and MexEF-OprN were
not observed among the clinical isolates of P. aeruginosa
evaluated in this study. Overall, 69.5% and 11.9% of
P. aeruginosa clinical isolates studied showed decreased
oprD expression (from 0.1- to 0.7-fold compared to
PAO1), and overexpression of ampC (from 14- to 402-
fold compared to PAO1), respectively. None of the
investigated resistance determinants was identified in
11.8% of clinical isolates (n = 7, Table 2).
Among the isolates overexpressing the mexY efflux
gene, 86.7% were not susceptible to amikacin, gentami-
cin and ciprofloxacin. Cefepime non-susceptibility was
observed in 80% of isolates overexpressing mexY.O f
those, 79.2% also presented reduced oprD transcription,
54.2% were MBL-producers, 12.5% produced the ESBL
GES-1, and 16.7% showed increased ampC transcrip-
tional levels (data not shown). Among the cefepime
non-susceptible isolates that did not show mexY over-
expression, 33.3% produced SPM-1, 33.3% overex-
pressed ampC, 16.7% produced the ESBL CTX-M-2,
and 16.7% produced GES-5, an ESBL with carbapene-
mase activity.
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Page 2 of 7Meropenem non-susceptibility was observed among
62.5% of isolates overexpressing mexB (from 2.1- to 5.5-
fold higher than PAO1). Of those, 90.0% showed
decreased oprD expression, 40.0% were MBL producers,
20.0% overexpressed ampC and 10.0% were GES-5 pro-
ducers (data not shown). As expected, all meropenem-
susceptible isolates that overexpressed mexB,p r e s e n t e d
normal expression of both ampC and oprD when com-
p a r e dt ot h a to fP A O 1 .H i g h e rp e r c e n t a g eo fmexB
overexpression was observed among isolates that were
also not susceptible to cefepime, amikacin, gentamicin
and ciprofloxacin. Of note, 85.7% and 28.6% of SPM-
producing P. aeruginosa showed increased transcrip-
tional levels of mexY and mexB, respectively.
It is worth to mention that MexAB-OprM and/or
MexXY-OprM overexpression was observed among
isolates that were susceptible to most antimicrobials
tested. This finding was expected since efflux pump
Table 1 The percentage of P. aeruginosa isolates that were non-susceptible to antimicrobials and demonstrated
overexpression of efflux genes and ampC b-lactamase, coupled with oprD down-regulation
Antimicrobial Non-susceptible (n = 59) % of isolates (n)
ABM+ (16) XY+ (30) AmpC+ (07) OprD- (41)
Aztreonam 21 (35.6) 56.3 (09) 43.3 (13) 71.4 (05) 34.1 (14)
Imipenem 31 (52.5) 56.3 (09) 80.0 (24) 71.4 (05) 65.9 (27)
Meropenem 31 (52.5) 62.5 (10) 80.0 (24) 71.4 (05) 63.4 (26)
Cefepime 30 (50.8) 56.3 (09) 80.0 (24) 85.7 (06) 58.5 (24)
Ceftazidime 33 (55.9) 50.0 (08) 76.7 (23) 100 (07) 63.4 (26)
Amikacin 35 (59.3) 68.8 (11) 86.7 (26) 57.1 (04) 70.7 (29)
Gentamicin 40 (67.8) 75.0 (12) 86.7 (26) 57.1 (04) 65.9 (27)
Ciprofloxacin 38 (64.4) 81.3 (13) 86.7 (26) 85.7 (06) 63.4 (26)
The abbreviations ABM+, XY+ and AmpC+ designate MexAB-OprM, MexXY, and AmpC overexpression, respectively.
OprD -: OprD porin down-regulation.
Table 2 Association of resistance mechanisms identified among the P. aeruginosa isolates (n = 59) and the modal MICs
for tested antimicrobials observed in each association
Isolates and determinant of antimicrobial resistance (No. of
isolates with OprD -)
Modal MIC
a(μg/ml)
MER IPM ATM CAZ FEP AMK GEN CIP
PAO1 reference strain - 0.25 1 4 0.5 0.25 2 4 0.25-
No mechanisms of resistance identified 7 (0) 4 2 4-8
b 42 8 4 1 6
XY+, MBL 7 (6) >32 >32 8 256 >32 >256 >256 >32
XY+ 7 (5) 16 8/16
b 32 8/256
b >32 256 2/>256
b 0.5/>32
b
ABM+, XY+ 5 (2) 0.25/8
b 0.25/2
b 16 8 4 256 2- >256
c 32
ABM+, XY+, MBL 4 (3) >32 >32 8 256 >32 >256 >256 >32
ABM+ 3 (2) 0.5-16
b 1 16 2-8
c 4 4-32
c 1-8
c 0.25-8
c
XY+, GES-1 3 (2) 8- >32
c 8- >32
c 8 128 >32 >256 256 16
ABM+, XY+, AmpC+ 2 (2) 16/>32
b >32 8/32
b 32/64
b 16/32
b 4/64
b 1/8
b 2/4
b
ABM+, GES-5 1 (1) >32 32 8 32 >32 128 128 32
ABM+, CTX-M2 1 (1) 4 1 >32 2 >32 128 256 16
XY+, AmpC+, MBL 2 (2) 32/>32
b >32 16/>32
b 128/>256
b >32 >256 >256 >32
MBL 2 (2) >32 >32 8 256 >32 >256 >256 32
AmpC+ 3 (2) 1-8 2-16
c 4-32
c 16-256
c 16 4 2 0.5-32
c
OprD- 12 (12) ≤0.25 1-2 8 2 2 8 2 0.25
MER, meropenem; IPM, imipenem; ATM, aztreonam; CAZ, ceftazidime; FEP, cefepime; AMK, amikacin; GEN, gentamicin; CIP, ciprofloxacin.
The abbreviations XY+, ABM+, and AmpC+ designate MexXY, MexAB-OprM, and AmpC overexpression, respectively.
MBL, metallo-b-lactamase producer
OprD-, reduced expression of OprD porin.
a, Modal MIC is defined as the antimicrobial MICs that were more frequently observed at each association of resistance mechanisms.
b, two modal MICs observed;
c MIC range when no modal MIC was observed.
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Page 3 of 7overexpression in P. aeruginosa usually confers modest
increase in the MICs of antimicrobial agents that are
ejected by these systems.
Discussion and Conclusions
P. aeruginosa is the fifth most frequent pathogen of
bloodstream infections and the first one causing pneu-
monia in Latin America according to the SENTRY Anti-
microbial Surveillance Program [13]. In the last decades,
the emergency of multi-drug resistant P. aeruginosa has
been observed worldwide. Some of antimicrobial agents
have become less effective against these organisms redu-
cing the available therapeutic options for treatment of
these infections.
In this study 52.5% of the P. aeruginosa isolates stu-
died were resistant to carbapenems. Our findings are in
accordance of previous studies that showed high rates of
antimicrobial resistance, including carbapenems, among
P. aeruginosa clinical isolates collected from Brazilian
institutions [14]. The genetic diversity observed among
the P. aeruginosa isolates studied indicates that spread
of clones and emergency of distinct genotypes have
occurred in our hospital. The high rate of carbapenem
resistance can be partially explained by the spread of an
endemic SPM-producing clone. It also justifies the sus-
ceptibility rate to aztreonam since MBL producers are
not able to hydrolyze this antimicrobial agent. This find-
ing corroborates with those previously reported that
described a single SPM producer clone spread out in
the Brazilian territory [15].
The overexpression of efflux systems may impact on
clinical outcome of P. aeruginosa infections since they
are capable of pumping out many classes of antimicro-
bial agents used for treatment of these infections [16].
However, it has not been clearly established the correla-
tion between increase in the transcriptional level of an
efflux-encoding gene and antimicrobial resistance lead-
ing to possible therapeutic failure [17].
In the present study, we have evaluated the transcrip-
tional levels of four efflux-encoding genes as well as
ampC and oprD among 59 P. aeruginosa clinical iso-
lates. This collection represents the total number of
patients with bloodstream infection due to P. aeruginosa
in a six-month period in Hospital São Paulo, Brazil. We
also aimed to evaluate the frequency of isolates present-
ing different mechanisms of b-lactam resistance and
their association.
The overexpression of the MexAB-OprM and
MexXY-OprM efflux systems were more frequent
among antimicrobial resistant P. aeruginosa isolates.
Since MexAB-OprM and MexXY-OprM are constitu-
tively expressed in wild type P. aeruginosa isolates, the
antimicrobial policy in use in each individual institu-
tion may interfere with the selection of the most
overexpressed efflux system. Aminoglycosides are
important substrates of MexXY-OprM and might have
exerted a role in selecting P. aeruginosa that overex-
pressed this system [18]. The expression of MexXY-
OprM is inducible, while expression of MexAB-OprM
is not [5]. In our institution, the prescription of amino-
glycosides is not controlled and these antimicrobial
agents usually are prescribed in combination for treat-
ment of P. aeruginosa infections. These facts could in
part justify why MexXY-OprM was the most frequent
overexpressed efflux system, since mexXY expression
may be induced by these antimicrobial class [19]. Inter-
estingly, the overexpression of MexXY-OprM was
observed in all MBL-producing isolates.
We did not notice a strict correlation between antimi-
crobial resistance and efflux genes overexpression. How-
ever, efflux overexpressing isolates often presented
higher antimicrobial MICs than did PAO1 and those
isolates in which no antimicrobial resistance determi-
nant was found.
Our findings clearly demonstrate that b-lactamase pro-
duction increase antimicrobial MICs more efficiently than
do efflux overexpression or porin down-regulation alone.
However, these chromosomal resistance mechanisms were
frequently present among acquired b-lactamase producers.
These findings suggest that efflux overexpression and
porin down-regulation may favor the bacterial survival
under selective pressure, increasing its chance to acquire
further resistance determinants.
In the present study we have observed that efflux pump
overexpression do not appear to be the main mechanism
of drug resistance among the studied clinical isolates of
P. aeruginosa, but represents an adjuvant mechanism for
antimicrobial resistance. The association of distinct
mechanisms such as the porin down-regulation and
AmpC overproduction play also an important role in the
multi-drug resistance phenotype among P. aeruginosa
clinical isolates studied. In addition, our findings indicate
that spread of clones and emergency of distinct geno-
types have occurred in our institution and implementa-
tion of control measures is extremely necessary to
modify this scenario.
Methods
Bacterial isolates and antimicrobial susceptibility testing
With the approval of the local Ethics in Research com-
mittee (Comitê de Ética em Pesquisa Hospital São
Paulo, protocol number: CEP0398/07), a total of 59 clin-
ical isolates of P. aeruginosa were evaluated, regardless
of their antimicrobial susceptibility profile. These iso-
lates were consecutively collected between June and
December 2005 from blood culture of patients hospita-
lized at Hospital São Paulo, a tertiary teaching hospital
located in São Paulo, Brazil. Only a single bacterial
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cefepime, aztreonam, imipenem, meropenem, gentami-
cin, amikacin and ciprofloxacin were determined by agar
dilution and interpreted according to Clinical Laboratory
Standards Institute [20,21]. P. aeruginosa ATCC 27853
and Escherichia coli ATCC 25922 strains were used as
quality control strains.
Pulsed Field Gel Electrophoresis
Genomic DNA of isolates was prepared in agarose
blocks and digested with the restriction enzyme SpeI
(New England, Beverly, MA). Electrophoresis was per-
formed on CHEF-DR III (BioRad, Richmond, CA), with
the following conditions: 0.5 × TBE, 1% agarose, 13°C,
200 V, for 24 h with switch time ramped from 5 to 90 s.
The band patterns were interpreted as previously
recommended [22].
Screening for carbapenemase producers and detection of
b-lactamases-encoding genes
Investigation of carbapenemase activity in crude extracts
was performed by UV spectrophotometric assays. Briefly,
a full 10 μl loop of the test organism was inoculated into
500 μl of phosphate buffer 100 mM (pH 7.0) and dis-
rupted by sonication. The cells were removed by centrifu-
gation and the supernatants were used for further
experiments. Protein quantification in the crude extracts
was performed using the Bradford stain. Hydrolytic activ-
ity of crude extracts was determined against 100 μMi m i -
penem and 100 μM meropenem in 100 mM phosphate
buffer (pH 7.0). Measurements were carried out at a
297nm wavelength. Positive control included SPM-1-
producing P. aeruginosa 48-1997A [23]. Carbapenem
hydrolysis inhibition was performed by incubating the
crude extract with 25 mM EDTA during 15 min,
previously to the assay with imipenem and meropenem.
Detection MBL-encoding genes was performed for
all carbapenem-resistant isolates by multiplex PCR,
as previously described [24]. The presence of ESBL-
encoding genes blaTEM, blaSHV, blaCTX-M, blaGES, blaVEB
and blaPER w a si n v e s t i g a t e db yP C R ,a sp r e v i o u s l y
reported [12,25].
Quantitative RT-PCR (RT-qPCR)
Transcriptional levels of mexB, mexD, mexF, mexY,
ampC and oprD were determined with Mastercycler
Realplex
2 (Eppendorf, Hamburg, Germany). In brief,
total RNA was extracted using the RNase Mini Kit, fol-
lowing the manufacturer recommendations (Qiagen,
Hilden, Germany). Five micrograms of total RNA was
submitted to cDNA synthesis using High Capacity
cDNA Archive Kit (Applied Biosystems, Foster City,
USA). Quantitative RT-PCR was performed with Plati-
num SYBR Green Supermix (Invitrogen, Carlsbad,
USA), using specific primers for mexB, mexD, mexF,
mexY, ampC and oprD as previously described [26-29]
or designed for this study using the GeneFisher online
software http://bibiserv.techfak.uni-bielefeld.de/gene-
fisher/old.html (Table 3). Amplification was carried out
in triplicate from cDNA preparations. To assure that
specific amplification had occurred, melting curves of
each amplicon was assessed and compared to that Tm
obtained when using PAO1 DNA total was tested as
template. A gene encoding the ribosomal protein rpsL
was used as a reference gene for normalizing the tran-
scriptional levels of target genes. Transcription data
were analyzed with the Q-Gene software [30]. According
to previous studies [31] the efflux systems MexAB-
Table 3 Primers used in this study for access the relative gene expression by RT-qPCR
Genes Primers Sequences (5’-3’) Amplicon size (bp) References
mexB mexB-F GTGTTCGGCTCGCAGTACTC 244 [26]
mexB-R AACCGTCGGGATTGACCTTG
mexD mexD-F CGAGCGCTATTCGCTGC 165 This study
mexD-R GGCAGTTGCACGTCGA
mexF mexF-F CGCCTGGTCACCGAGGAAGAGT 255 [27]
mexF-R TAGTCCATGGCTTGCGGGAAGC
mexY mexY-F CCGCTACAACGGCTATCCCT 250 [26]
mexY-R AGCGGGATCGACCAGCTTTC
oprD oprD-F TCCGCAGGTAGCACTCAGTTC 191 [28]
oprD-R AAGCCGGATTCATAGGTGGTG
ampC ampC-F CTGTTCGAGATCGGCTC 166 This study
ampC-R CGGTATAGGTCGCGAG
rpsL rpsL-F GCAAGCGCATGGTCGACAAGA 201 [29]
rpsL-R CGCTGTGCTCTTGCAGGTTGTGA
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considered overexpressed when the transcriptional levels
of mexB, mexC, mexE,a n dmexY were at least 2, 100,
100, and 4 fold higher than those of the wild-type refer-
ence strain PAO1, respectively. Reduced oprD expres-
sion and overexpression of ampC were considered
relevant when their transcriptional levels were ≤70% and
≥10-fold, respectively, compared to that of the PAO1
reference strain [10,32].
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